NextCell invited speaker at European Wound Management Association Meeting in Milan

NextCell Pharma AB´s ("NextCell" orthe "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell´s phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.

Dr Davies, in addition to her role at NextCell, is a member of the scientific advisory board for the European Tissue Repair Society (ETRS). ETRS and EWMA have partnered for a session at the annual conference, that brings together wound management researchers, clinicians and industrial partners to discuss innovative therapies and treatment options forwound patients.

Dr Davies has been invited to speak at the conference on 4^th May. Her presentation is entitled, “Mesenchymal stromal cells – a novel approach to the treatment of type 1 diabetes”. The meeting will be held at MICo Milano Convention Centre, Milan, Italy, from Wednesday 3^rd to Friday 5^th of May.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel:08-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍